Nephrogenic systemic fibrosis: the end of the story?

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F19%3AN0000170" target="_blank" >RIV/00064173:_____/19:N0000170 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.21037/qims.2019.07.11" target="_blank" >https://doi.org/10.21037/qims.2019.07.11</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21037/qims.2019.07.11" target="_blank" >10.21037/qims.2019.07.11</a>

Result language
angličtina
Original language name
Nephrogenic systemic fibrosis: the end of the story?
Original language description
Gadolinium-based contrast agents (GBCA) have been standardly intravenously applied to improve visibility of MRI examinations since 1988, when gadopentetate dimeglumine (Magnevist(R)) was approved for clinical practice. Gadolinium itself is a heavy metal, highly toxic in biological systems. Therefore, gadolinium must be bound to ligands for the purpose of contrast agents. GBCA consist of gadolinium ion and a chelating molecule, which could be cyclic or linear. The macrocyclic molecule pre-organizes the rigid ring to cage the gadolinium ion, which offers better protection and binding of gadolinium ion. Linear chelates with a flexible open chain are less stable and provide weaker link of the gadolinium ion. The rate of gadolinium dissociation from the macrocyclic ligands is remarkably slower than their dissociation from the linear chelates.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30224 - Radiology, nuclear medicine and medical imaging

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)